Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function

被引：0
|
作者：
Michelle Treitel
Thomas Marbury
Richard A. Preston
Ilias Triantafyllou
William Feely
Edward O’Mara
Claudia Kasserra
Samir Gupta
Eric A. Hughes
机构：
[1] Merck Sharp & Dohme Corp.,Division of Clinical Pharmacology Research Unit, Miller School of Medicine
[2] Orlando Clinical Research Center,Merck Research Laboratories
[3] University of Miami,undefined
[4] Merck & Co.,undefined
来源：
Clinical Pharmacokinetics | 2012年 / 51卷 / 9期
关键词：
Hepatic Impairment; Boceprevir; Severe Hepatic Impairment; Mild Hepatic Impairment; Median Tmax;
D O I：
10.1007/BF03261935
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：619 / 628
页数：9
相关论文
共 50 条
  • [1] Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function
    Treitel, Michelle
    Marbury, Thomas
    Preston, Richard A.
    Triantafyllou, Ilias
    Feely, William
    O'Mara, Edward
    Kasserra, Claudia
    Gupta, Samir
    Hughes, Eric A.
    [J]. CLINICAL PHARMACOKINETICS, 2012, 51 (09) : 619 - 628
  • [2] The single-dose pharmacokinetics of carisbamate in subjects with normal and impaired hepatic function.
    Moore, K. T.
    Zannikos, P.
    Solanki, B.
    Greenspan, A.
    Romano, G.
    Brashear, H.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S24 - S24
  • [3] Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment
    Thyrum, PT
    Wong, YWJ
    Yeh, C
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2000, 24 (04): : 521 - 533
  • [4] Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment
    Garimella, Tushar
    Wang, Reena
    Luo, Wen-Lin
    Hwang, Carey
    Sherman, Diane
    Kandoussi, Hamza
    Marbury, Thomas C.
    Alcorn, Harry
    Bertz, Richard
    Bifano, Marc
    [J]. ANTIVIRAL THERAPY, 2015, 20 (05) : 535 - 543
  • [5] Pharmacokinetics of single dose cerivastatin in subjects with normal and impaired renal function
    Vormfelde, SV
    Gleiter, CH
    Freudenthaler, S
    Muck, W
    Schmage, N
    Kuhlmann, J
    GundertRemy, U
    [J]. ATHEROSCLEROSIS, 1997, 130 : 127 - 127
  • [6] Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis
    Choudhury, S
    Hirschberg, Y
    Filipek, R
    Lasseter, K
    McLeod, JF
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (06): : 634 - 640
  • [7] Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment
    Barbhaiya, RH
    Shukla, UA
    Greene, DS
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 49 (03) : 221 - 228
  • [8] SINGLE-DOSE PHARMACOKINETICS OF LOMEFLOXACIN IN PATIENTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION
    NILSEN, OG
    SALTVEDT, E
    WALSTAD, RA
    MARSTEIN, S
    [J]. AMERICAN JOURNAL OF MEDICINE, 1992, 92 : S38 - S40
  • [9] Bucindolol single dose pharmacokinetics (PK) in subjects with impaired hepatic function.
    Ogunremi, A
    Gehr, T
    Sica, D
    Sellers, J
    Roberge, P
    Ward, D
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 158 - 158
  • [10] Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis
    Johnson, MA
    Verpooten, GA
    Daniel, MJ
    Plumb, R
    Moss, J
    Van Caesbroeck, D
    De Broe, ME
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (01) : 21 - 27
12345